|
1
|
Crisponi L, Deiana M, Loi A, Chiappe F,
Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, et al:
The putative forkhead transcription factor FOXL2 is mutated in
blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet.
27:159–166. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cocquet J, Pailhoux E, Jaubert F, Servel
N, Xia X, Pannetier M, De Baere E, Messiaen L, Cotinot C, Fellous M
and Veitia RA: Evolution and expression of FOXL2. J Med Genet.
39:916–921. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loffler KA, Zarkower D and Koopman P:
Etiology of ovarian failure in blepharophimosis ptosis epicanthus
inversus syndrome: FOXL2 is a conserved, early-acting gene in
vertebrate ovarian development. Endocrinology. 144:3237–3243. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottolenghi C, Omari S, Garcia-Ortiz JE,
Uda M, Crisponi L, Forabosco A, Pilia G and Schlessinger D: Foxl2
is required for commitment to ovary differentiation. Hum Mol Genet.
14:2053–2062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burns KH, Owens GE, Fernandez JM, Nilson
JH and Matzuk MM: Characterization of integrin expression in the
mouse ovary. Biol Reprod. 67:743–751. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uhlenhaut NH, Jakob S, Anlag K,
Eisenberger T, Sekido R, Kress J, Treier AC, Klugmann C, Klasen C,
Holter NI, et al: Somatic sex reprogramming of adult ovaries to
testes by FOXL2 ablation. Cell. 139:1130–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schmidt D, Ovitt CE, Anlag K, Fehsenfeld
S, Gredsted L, Treier AC and Treier M: The murine winged-helix
transcription factor Foxl2 is required for granulosa cell
differentiation and ovary maintenance. Development. 131:933–942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalfa N, Philibert P, Patte C, Ecochard A,
Duvillard P, Baldet P, Jaubert F, Fellous M and Sultan C:
Extinction of FOXL2 expression in aggressive ovarian granulosa cell
tumors in children. Fertil Steril. 87:896–901. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moumne L, Batista F, Benayoun BA,
Nallathambi J, Fellous M, Sundaresan P and Veitia RA: The mutations
and potential targets of the forkhead transcription factor FOXL2.
Mol Cell Endocrinol. 282:2–11. 2008. View Article : Google Scholar
|
|
10
|
Rosario R, Araki H, Print CG and Shelling
AN: The transcriptional targets of mutant FOXL2 in granulosa cell
tumours. PLoS One. 7:e462702012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horvath P and Barrangou R: CRISPR/Cas, the
immune system of bacteria and archaea. Science. 327:167–170. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Terns MP and Terns RM: CRISPR-based
adaptive immune systems. Curr Opin Microbiol. 14:321–327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wiedenheft B, Sternberg SH and Doudna JA:
RNA-guided genetic silencing systems in bacteria and archaea.
Nature. 482:331–338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai
SQ, Sander JD, Peterson RT, Yeh JR and Joung JK: Efficient genome
editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol.
31:227–229. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cong L, Ran FA, Cox D, Lin S, Barretto R,
Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F:
Multiplex genome engineering using CRISPR/Cas systems. Science.
339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Yang H, Shivalila CS, Dawlaty MM,
Cheng AW, Zhang F and Jaenisch R: One-step generation of mice
carrying mutations in multiple genes by CRISPR/Cas-mediated genome
engineering. Cell. 153:910–918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang T, Wei JJ, Sabatini DM and Lander ES:
Genetic screens in human cells using the CRISPR-Cas9 system.
Science. 343:80–84. 2014. View Article : Google Scholar
|
|
18
|
Shalem O, Sanjana NE, Hartenian E, Shi X,
Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG and
Zhang F: Genome-scale CRISPR-Cas9 knockout screening in human
cells. Science. 343:84–87. 2014. View Article : Google Scholar :
|
|
19
|
Lee PC, Truong B, Vega-Crespo A, Gilmore
WB, Hermann K, Angarita SA, Tang JK, Chang KM, Wininger AE, Lam AK,
et al: Restoring ureagenesis in hepatocytes by CRISPR/Cas9-mediated
genomic addition to arginase-deficient induced pluripotent stem
cells. Mol Ther Nucleic Acids. 5:e3942016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tu Z, Yang W, Yan S, Guo X and Li XJ:
CRISPR/Cas9: A powerful genetic engineering tool for establishing
large animal models of neurodegenerative diseases. Mol
Neurodegener. 10:352015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X,
Xiong JW and Xi JJ: Genome editing with RNA-guided Cas9 nuclease in
zebrafish embryos. Cell Res. 23:465–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao S, He Z and Chen C:
CRISPR/Cas9-mediated genome editing of epigenetic factors for
cancer therapy. Hum Gene Ther. 26:463–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gebler C, Lohoff T, Paszkowski-Rogacz M,
Mircetic J, Chakraborty D, Camgoz A, Hamann MV, Theis M, Thiede C
and Buchholz F: Inactivation of cancer mutations utilizing
CRISPR/Cas9. J Natl Cancer Inst. 109:pii: djw1832016. View Article : Google Scholar
|
|
24
|
Kawamura N, Nimura K, Nagano H, Yamaguchi
S, Nonomura N and Kaneda Y: CRISPR/Cas9-mediated gene knockout of
NANOG and NANOGP8 decreases the malignant potential of prostate
cancer cells. Oncotarget. 6:22361–22374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Verdin H and De Baere E: FOXL2 impairment
in human disease. Horm Res Paediatr. 77:2–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tran S, Zhou X, Lafleur C, Calderon MJ,
Ellsworth BS, Kimmins S, Boehm U, Treier M, Boerboom D and Bernard
DJ: Impaired fertility and FSH synthesis in gonadotrope-specific
Foxl2 knockout mice. Mol Endocrinol. 27:407–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi F, Ding S, Zhao S, Han M, Zhuang Y, Xu
T and Wu X: A piggyBac insertion disrupts Foxl2 expression that
mimics BPES syndrome in mice. Hum Mol Genet. 23:3792–3800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Doudna JA and Charpentier E: Genome
editing. The new frontier of genome engineering with CRISPR-Cas9.
Science. 346:12580962014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsu PD, Lander ES and Zhang F: Development
and applications of CRISPR-Cas9 for genome engineering. Cell.
157:1262–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harrison MM, Jenkins BV, O’Connor-Giles KM
and Wildonger J: A CRISPR view of development. Genes Dev.
28:1859–1872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sander JD and Joung JK: CRISPR-Cas systems
for editing, regulating and targeting genomes. Nat Biotechnol.
32:347–355. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsu PD, Scott DA, Weinstein JA, Ran FA,
Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, et al: DNA
targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol.
31:827–832. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blount AL, Schmidt K, Justice NJ, Vale WW,
Fischer WH and Bilezikjian LM: FoxL2 and Smad3 coordinately
regulate follistatin gene transcription. J Biol Chem.
284:7631–7645. 2009. View Article : Google Scholar :
|
|
36
|
Huang SM, Lu KT and Wang YC: ATM/ATR and
SMAD3 pathways contribute to 3-indole-induced G1 arrest
in cancer cells and xenograft models. Anticancer Res. 31:203–208.
2011.PubMed/NCBI
|
